uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Modeling of busulfan pharmacokinetics and relapses in adult patients with acute myeloid leukemia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2012 (English)Independent thesis Advanced level (degree of Master (One Year)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Introduction: Busulfan is used as a conditioning drug prior to bone marrow transplants in patients with acute myeloid leukemia. To achieve busulfan target exposure, therapeutic drug monitoring is common clinical practice where rich pharmacokinetic (PK) sampling is utilized. Despite of doing so, the clinical outcome still greatly varies. Cytogenetics are one of the main factors for predicting disease outcome.

Aim: The objective of this project was to characterize busulfan population PK. Secondary aims were to (i) optimize the number of samples needed to estimate busulfan exposure and (ii) to develop a model characterizing relapse/death incidence incorporating different predictors.

Methods: Data were compiled from a UCSF patient database. Standard non-linear mixed effects methodology was utilized for the model building. A proportional odds model was applied to characterize probability of a relapse/death. Busulfan exposure as well as 50 genes identified as top hits by GWAS were tested as potential predictors of relapses.Results: Population estimates of clearance and volume of distribution (typical patient 75 kg), were 0.156 L/h/kg and 0.604 L/kg with between-subject variability of 19.6% and 17.5%, respectively. One sample in combination with the developed model is sufficient to dose adjust and reach target exposure (relative predictive error < 2% compared to current clinical practice). Probability of relapse/death was associated with cytogenetic factors (rs555513, rs10122691), showing modified risk of relapse/death depending on genotype.

Conclusions: Current clinical practices used to achieve target busulfan exposure can be simplified by utilizing the developed model. The number of PK samples can be reduced from four to one, thereby lowering costs and improving overall quality of life for the patient. The identified cytogenetic predictors of relapse/death are in line with results obtained from the GWAS study, which was carried out in parallel.

Place, publisher, year, edition, pages
2012. , 24 p.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-185687OAI: oai:DiVA.org:uu-185687DiVA: diva2:572365
External cooperation
Rada Savic, Univeristy of California, San Francisco
Subject / course
Pharmacokinetics
Educational program
Master of Science Programme in Pharmacy
Uppsok
Medicine
Supervisors
Examiners
Available from: 2013-02-28 Created: 2012-11-27 Last updated: 2013-02-28Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Pharmaceutical Biosciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 590 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf